Edgewood Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Edgewood Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-73,599	Closed	-$51K	–	84
2020 Q4	$51K	Hold	73,599	–	–	﹤0.01%	81
2020 Q3	$166K	Hold	73,599	–	–	﹤0.01%	75
2020 Q2	$263K	Hold	73,599	–	–	﹤0.01%	68
2020 Q1	$280K	Sell	73,599 -400	-0.5%	-$1.32K	﹤0.01%	66
2019 Q4	$223K	Buy	+73,999	New	+$192K	﹤0.01%	79

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Edgewood Management's BMY.RT Position: Q1 2021 in Review

Edgewood Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 73,599 shares — an estimated $51K sold.

Edgewood Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $280K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Edgewood Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Edgewood Management sold 73,599 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $51K.
Edgewood Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Edgewood Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $280K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Edgewood Management's 13F filing for Q1 2021, filed 13 May 2021.